Lymphoma, T-Cell, Cutaneous Clinical Trial
Official title:
Searching for Oncogenic Viruses in Sézary Cells Using a Novel Viral Discovery Technique, VirCapSeq-VERT
NCT number | NCT02836886 |
Other study ID # | AAAQ9017 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 2016 |
Est. completion date | October 2016 |
Verified date | May 2024 |
Source | Columbia University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will be using this technique, called "VirCapSeq-VERT" to analyze the white blood cells of patients with Sézary syndrome. This could provide the foundation for future studies looking to understand the role that viruses play in the origin of Sézary syndrome. This could have important implications for the future development of new and effective therapies for the disease.
Status | Completed |
Enrollment | 6 |
Est. completion date | October 2016 |
Est. primary completion date | October 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients with Sézary syndrome diagnosed according to the WHO-EORTC classification. Exclusion Criteria: - Pregnant patients. - Patients with known anemia with documented <7.5 mg/dL. - Patients who are unable to give informed consent. |
Country | Name | City | State |
---|---|---|---|
United States | Columbia University Medical Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Columbia University |
United States,
Anderson ME, Nagy-Szakal D, Jain K, Patrone CC, Frattini MG, Lipkin WI, Geskin LJ. Highly Sensitive Virome Capture Sequencing Technique VirCapSeq-VERT Identifies Partial Noncoding Sequences but no Active Viral Infection in Cutaneous T-Cell Lymphoma. J Invest Dermatol. 2018 Jul;138(7):1671-1673. doi: 10.1016/j.jid.2018.01.024. Epub 2018 Feb 7. No abstract available. — View Citation
Briese T, Kapoor A, Mishra N, Jain K, Kumar A, Jabado OJ, Lipkin WI. Virome Capture Sequencing Enables Sensitive Viral Diagnosis and Comprehensive Virome Analysis. mBio. 2015 Sep 22;6(5):e01491-15. doi: 10.1128/mBio.01491-15. Erratum In: MBio. 2017 May 16;8(3): — View Citation
Henn A, Michel L, Fite C, Deschamps L, Ortonne N, Ingen-Housz-Oro S, Marinho E, Beylot-Barry M, Bagot M, Laroche L, Crickx B, Maubec E. Sezary syndrome without erythroderma. J Am Acad Dermatol. 2015 Jun;72(6):1003-9.e1. doi: 10.1016/j.jaad.2014.11.015. — View Citation
Lessin SR, Vowels BR, Rook AH. Retroviruses and cutaneous T-cell lymphoma. Dermatol Clin. 1994 Apr;12(2):243-53. — View Citation
Mirvish JJ, Pomerantz RG, Falo LD Jr, Geskin LJ. Role of infectious agents in cutaneous T-cell lymphoma: facts and controversies. Clin Dermatol. 2013 Jul-Aug;31(4):423-431. doi: 10.1016/j.clindermatol.2013.01.009. — View Citation
Siegel RS, Pandolfino T, Guitart J, Rosen S, Kuzel TM. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol. 2000 Aug;18(15):2908-25. doi: 10.1200/JCO.2000.18.15.2908. Erratum In: J Clin Oncol 2001 Nov 1;19(21):4185. — View Citation
Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, Grange F, Harris NL, Kempf W, Kerl H, Kurrer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Sterry W, Vermeer MH, Wechsler J, Whittaker S, Meijer CJ. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005 May 15;105(10):3768-85. doi: 10.1182/blood-2004-09-3502. Epub 2005 Feb 3. — View Citation
Willerslev-Olsen A, Krejsgaard T, Lindahl LM, Bonefeld CM, Wasik MA, Koralov SB, Geisler C, Kilian M, Iversen L, Woetmann A, Odum N. Bacterial toxins fuel disease progression in cutaneous T-cell lymphoma. Toxins (Basel). 2013 Aug 14;5(8):1402-21. doi: 10.3390/toxins5081402. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Number of Coding Sequences for Viral Pathogens Extracted From T Cells of Patients With Sézary Syndrome | Through study completion, an average of 4 months | ||
Primary | Number of Participants With Viral Sequences Present in Malignant T Cells of Patients With Sézary Syndrome | Through study completion, an average of 4 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03357224 -
PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)
|
Phase 2 | |
Completed |
NCT02567656 -
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma
|
Phase 1 | |
Completed |
NCT00051012 -
Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients
|
Phase 4 | |
Recruiting |
NCT03646422 -
AEDV Registry of Primary Cutaneous Lymphoma
|
||
Terminated |
NCT03789864 -
Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides
|
N/A | |
Active, not recruiting |
NCT04998331 -
A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin
|
||
Active, not recruiting |
NCT02953301 -
Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)
|
Phase 2 | |
Completed |
NCT01433731 -
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
|
Phase 1 | |
Completed |
NCT01486277 -
A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma
|
Phase 2 | |
Completed |
NCT05137847 -
A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
|
||
Active, not recruiting |
NCT03902184 -
IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
|
Phase 2 | |
Completed |
NCT00896493 -
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
|
Phase 2 | |
Completed |
NCT00211198 -
Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)
|
Phase 4 | |
Terminated |
NCT03601819 -
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
|
Phase 1 | |
Withdrawn |
NCT03742804 -
Study Of Intratumoral G100 In Cutaneous T Cell Lymphoma
|
Phase 2 | |
Completed |
NCT00050999 -
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients
|
Phase 4 | |
Terminated |
NCT02323659 -
Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas
|
Phase 4 | |
Recruiting |
NCT02840747 -
Tissue Repository: CTCL Collection Protocol
|
||
Completed |
NCT03192202 -
AFM13 in Relapsed/Refractory Cutaneous Lymphomas
|
Phase 1/Phase 2 | |
Terminated |
NCT02811783 -
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL
|
Phase 3 |